Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC.

Hongxiang Huang,Peiyuan Zhong,Xie Zhu, Silv Fu,Siling Li,Sujuan Peng,Yangyang Liu,Zhihui Lu,Li Chen

Frontiers in oncology（2023）

引用 0|浏览2

暂无评分

摘要

Our study showed that ICI therapy combined with endostatin therapy exhibits high efficacy and safety, suggesting that such a combination might be a viable treatment option for patients with pre-treated NSCLC in the future.

查看译文

关键词

angiogenesis inhibitors,chemotherapy,immune checkpoint inhibitors,non-small cell lung cancer,tumor microenvironments

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要